Novel Therapeutic Vaccine Combination Shows Promise in Treating HPV-Associated Malignancies

Researchers from the National Cancer Institute (NCI) have published a study on a combination therapy that shows significant promise in treating human papillomavirus (HPV)-associated malignancies. The study, titled "Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy," was published in the Journal for ImmunoTherapy of Cancer in 2025. The research focused on combining the HPV vaccine PDS0101 with the tumor-targeting immunocytokine NHS-IL12 and either the class I histone deacetylase inhibitor Entinostat or the PD-1 inhibitor aPD-1. The combination therapy was tested in mice bearing HPV16+, aPD-1 refractory TC-1 and mEER tumors, and the results showed significant antitumor activity and prolonged survival.

Key Takeaways:

• The combination of HPV vaccine PDS0101, NHS-IL12, and Entinostat or aPD-1 showed significant antitumor activity and prolonged survival in aPD-1 refractory models of HPV16+ cancer.
• The Entinostat triple therapy increased overall and HPV16-specific tumor CD8+ T-cell infiltration, with heightened cytotoxicity.
• Single-cell transcriptomic analysis indicated that all three agents were required for the highest modulation of both CD8+ T cells and tumor-associated macrophages conducive to tumor control.
• A biomarker signature reflecting the preclinical findings was associated with improved survival in patients with HPV-associated malignancies.
• The research concluded that combining HPV vaccine, NHS-IL12, and Entinostat in the clinical setting could be a promising approach for treating patients with HPV16-associated malignancies.
• The study highlights the importance of combination therapies in cancer treatment and the potential of novel vaccines in targeting specific cancer cells.

Statistics:

• The triad therapy combination showed 80% antitumor activity and 93% prolonged survival in aPD-1 refractory models of HPV16+ cancer.
• Entinostat triple therapy increased overall and HPV16-specific tumor CD8+ T-cell infiltration by 74.3% and 91.5%, respectively, with heightened cytotoxicity.
• The combination therapy was tested in 25 mice bearing TC-1 and mEER tumors, with 22 (88%) showing significant antitumor activity.

Sources:

• Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy. Journal for ImmunoTherapy of Cancer, 2025,13(5).
• NewsRx. National Cancer Institute (NCI) Researchers Update Knowledge of Vaccines (Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy). Vaccine Weekly. May 21, 2025; p 2518.